セルベースアッセイ（Cell-based Assay）のグローバル市場動向（～2018）...市場調査レポートについてご紹介

Table Of Contents

1 Introduction (Page No. – 19)
1.1 Objectives of the Study
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Market Scope
1.6 Research Methodology
1.6.1 Market Size Estimation
1.6.2 Market Crackdown & Data Triangulation
1.6.3 Key Data From Secondary Sources
1.6.4 Key Data Points From Primary Sources
1.6.5 Assumptions

2 Executive Summary (Page No. – 32)

3 Premium Insights (Page No. – 36)
3.1 Global Cell-Based Assays Market
3.2 Market Dynamics
3.3 Snapshot of the Market
3.4 Consumables & Instruments Market For Cell-Based Assays
3.5 Geographic Analysis
3.6 Application Market
3.7 End User Market

4 Market Overview (Page No. – 43)
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Significant Advantages of Cell-Based Assays Over Conventional Techniques Provide Ideal Solution For A Range of Research & Commercial Applications
4.2.1.2 Government Funding and Public-Private Partnerships Support Cell-Based Research Activities
4.2.1.3 Drug Discovery, Major Driver For Cell-Based Assays Market
4.2.1.4 Implementation of Hts and Automation Techniques Accelerates the Drug Discovery Process
4.2.2 Restraints
4.2.2.1 Shortage of Skilled Experts & High Instrument Costs Have A Negative Impact
4.2.2.2 Skepticism About Long-Term Benefits of Reporter Assay Kits May Affect their Adoption
4.2.2.3 Intellectual Property Rights Issues Restrict Innovations in the Market
4.2.3 Opportunities
4.2.3.1 Asian Market Presents High-Growth Opportunities
4.2.3.2 Need to De-Risk Early-Phase Drug Discovery Reinforces Cell-Based toxicity Screening
4.2.3.3 Developments in High-Content Screening and Software to Transform Cell-Based Screening
4.2.4 Trends
4.2.4.1 Use of Stem Cells & 3d Culture Defines the Future of the Market
4.2.4.2 Assay Development and Assay Screening Services Are the Most Prominent Trend
4.2.4.3 Label-Free Technologies Are Set to Transform the Market
4.3 Burning Issues & Challenges
4.3.1 Consistent Supply of Cells Creates A Bottleneck
4.3.2 New Technologies Call For Assay Optimization
4.4 Winning Imperatives
4.4.1 Assay Multiplexing
4.4.2 Assay Miniaturization & Microfluidics
4.5 Porter’s Five Forces Analysis
4.5.1 Threat From New Entrants
4.5.2 Threat From Substitutes
4.5.3 Competitors Rivalry
4.5.4 Bargaining Power of Suppliers
4.5.5 Bargaining Power of Buyers
4.6 Market Share Analysis

5 Cell-Based Assays Market, By Product (Page No. – 63)
5.1 Introduction
5.2 Consumables
5.2.1 Reagents & Assay Kits
5.2.1.1 Cell Growth Assays
5.2.1.2 Cell Death Assays
5.2.1.3 Second Messenger Assays
5.2.1.4 Reporter Gene Assays
5.2.1.5 Other Assays
5.2.2 Microplates
5.2.3 Cell Lines
5.2.3.1 Immortalized Cell Lines
5.2.3.2 Primary Cell Lines
5.2.3.3 Stem Cell Lines
5.2.4 Other Consumables
5.3 Instruments
5.3.1 Detection & Screening Instruments
5.3.1.1 Microplate Readers
5.3.1.2 Flow Cytometers
5.3.1.3 Fluorescent Microscopes
5.3.1.4 High Content Screening Instruments
5.3.1.5 Label-Free Detection Instruments
5.3.1.6 Other Detection and Screening Instruments
5.3.2 Automation & High Throughput Screening Instruments
5.4 Software
5.5 Services

6 Cell-Based Assays Market, By Application (Page No. – 109)
6.1 Introduction
6.2 Basic Research
6.3 Drug Discovery
6.3.1 Target Identification and Validation
6.3.2 Lead Identification & Optimization
6.4 Absorption, Distribution, Metabolism & Excretion (Adme) Studies
6.5 Predictive Toxicology
6.6 Other Applications

7 Cell-Based Assays Market, By End User (Page No. – 126)
7.1 Introduction
7.2 Pharmaceutical & Biotechnology Companies
7.3 Academic & Government Institutions
7.4 Contract Research Organizations (CRO)
7.5 Other End Users (Hospitals/Clinical Labs, Food/ Agriculture Industries & Environmental Labs)

8 Cell-Based Assays, By Geography (Page No. – 136)
8.1 Introduction
8.2 North America
8.2.1 Emphasis on Technological Advancements Drives the U.S. Market
8.2.2 Research Networks in Canada to Boost the Market
8.3 Europe
8.3.1 Decline in Venture Capitalist Investments in Early Drug Discovery Shifts the Burden to Public Funding
8.3.2 Public-Private Partnerships to Accelerate Drug Discovery Process in European Union
8.4 Asia
8.4.1 Stem Cell Research in Japan
8.4.2 Drug Discovery Outsourcing Fuels the Market Growth in China and India
8.5 ROW

9 Competitive Landscape (Page No. – 179)
9.1 Introduction
9.2 New Product Launch
9.3 Agreements, Collaborations & Partnerships
9.4 Acquisitions
9.5 Others

10 Company Profiles (Page No. – 188)
10.1 Becton, Dickinson and Company
10.2 Cell Signaling Technology
10.3 Cisbio Bioassays (Argos Soditic)
10.4 Danaher Corporation
10.5 Discoverx
10.6 EMD Millipore (A Subsidiary of Merck Kgaa)
10.7 Ge Healthcare (Subsidiary of General Electric Company)
10.8 Life Technologies (Thermo Fisher Scientific)
10.9 Perkinelmer, Inc.
10.10 Promega Corporation

*Details on Business Overview, Financials, Product & Services, Key Strategy, & Recent Developments Might Not Be Captured in Case of Unlisted Companies.